Date: Thursday, February 26, 2015
Time: 12:00 PM Eastern Standard Time
Duration: 1 hour

Click here to Register.


Historically it has taken the industry 20-30 months from the start of the monoclonal antibody (mAb) discovery process to final selection of lead drug candidates. Often this process has to be repeated to obtain the best candidates with the desired drug properties. With increasing pressures to meet timelines and the need to conserve financial resources the demands to efficiently and effectively discover your final mAb therapeutic candidate has never been greater.

What can be done to decrease the time required for candidate selection?

This webinar will answer that question by evaluating an integrated mAb discovery process which utilizes multiple technology platforms to improve the quality of therapeutic lead candidates. In addition, using an integrated project team and reducing the number of vendors to speed the time to lead antibody candidate selection will be discussed. Case studies will be presented.



Jing Li, MD, PhD, MBA
Vice President, Biologics Discovery
WuXi Biologics (A Division of WuXi AppTec)

George Wang, MD, PhD, MBA
Executive Director, Protein Engineering and Novel Format
WuXi Biologics (A Division of WuXi AppTec)

Event contact:

Linda Zhou